european
commission
grants
marketing
authorization
filgotinib
treatment
adults
moderate
severe
active
rheumathoid
arthritis
brussels
stock
exchange
glpg
demonstrated
durable
efficacy
combined
consistent
safety
profile
rheumatoid
arthritis
weeks
phase
clinical
development
program
foster
city
mechelen
belgium
september
cet
gilead
sciences
nasdaq
gild
galapagos
nv
euronext
nasdaq
glpg
today
announced
european
commission
ec
granted
marketing
authorization
filgotinib
mg
mg
tablets
oral
inhibitor
treatment
adults
moderate
severe
active
rheumatoid
arthritis
ra
responded
inadequately
intolerant
one
disease
modifying
drugs
dmards
jyseleca
may
used
monotherapy
combination
methotrexate
mtx
ra
chronic
progressive
systemic
inflammatory
disease
lead
significant
irreversible
joint
destruction
pain
functional
almost
million
people
europe
living
many
achieve
symptom
control
lead
frequent
symptom
flares
disease
progression
significantly
impact
quality
despite
availability
existing
therapies
new
treatment
options
still
needed
help
optimally
manage
impact
ra
patients
daily
lives
jyseleca
demonstrated
robust
symptom
control
prevention
disease
progression
consistent
safety
profile
across
clinical
development
program
marketing
authorization
provides
welcome
new
option
people
europe
living
debilitating
complex
disease
said
peter
taylor
bm
bch
phd
frcp
professor
musculoskeletal
sciences
university
oxford
ec
decision
supported
data
patients
treated
jyseleca
across
phase
finch
phase
darwin
finch
studies
jyseleca
consistently
achieved
criteria
improvements
individual
acr
components
compared
placebo
significantly
higher
proportion
patients
treated
jyseleca
mg
plus
mtx
conventional
synthetic
drug
csdmard
achieved
low
disease
activity
remission
weeks
compared
placebo
patients
inadequate
response
mtx
treatment
jyseleca
plus
mtx
achieved
statistically
significant
inhibition
progression
structural
joint
damage
compared
placebo
plus
mtx
assessed
using
modified
total
sharp
score
mtss
week
darwin
phase
extension
study
durable
responses
maintained
three
years
patients
received
jyseleca
mg
monotherapy
across
finch
darwin
common
adverse
reactions
nausea
upper
respiratory
tract
infection
urinary
tract
infection
rates
herpes
zoster
pneumonia
frequency
serious
infections
jyseleca
mg
group
percent
compared
percent
placebo
integrated
safety
analysis
seven
clinical
trials
rates
major
adverse
cardiac
events
mace
venous
thromboembolism
vte
jyseleca
comparable
rates
serious
infections
remained
stable
jyseleca
first
medicine
galapagos
obtain
regulatory
approval
result
strong
commitment
addressing
unmet
medical
need
said
daniel
day
chairman
chief
executive
officer
gilead
sciences
look
forward
making
continued
progress
collaboration
galapagos
help
deliver
many
new
solutions
patients
today
announcement
proud
day
everyone
galapagos
recognizing
years
research
commitment
make
meaningful
change
lives
patients
struggling
symptoms
ra
said
onno
van
de
stolpe
chief
executive
officer
galapagos
news
affirms
efficacy
safety
profile
jyseleca
look
forward
bringing
important
treatment
physicians
patients
across
europe
quickly
collaboration
agreement
galapagos
receive
milestone
payment
million
recognition
approval
jyseleca
european
commission
finch
program
finch
phase
program
investigated
efficacy
safety
jyseleca
mg
mg
ra
patient
populations
ranging
early
stage
patients
finch
randomized
trial
combination
mtx
enrolling
adult
patients
moderate
severe
active
ra
inadequate
response
mtx
primary
endpoint
finch
week
trial
included
radiographic
assessment
weeks
finch
global
randomized
phase
study
evaluating
jyseleca
background
csdmards
among
adult
patients
moderate
severe
active
ra
adequately
responded
biologic
dmards
bdmards
primary
endpoint
finch
week
finch
randomized
trial
patients
evaluate
jyseleca
mg
alone
jyseleca
mg
mg
combined
mtx
versus
mtx
alone
patients
primary
endpoint
finch
week
trial
included
radiographic
assessment
weeks
filgotinib
collaboration
gilead
galapagos
nv
collaborative
partners
global
development
commercialization
filgotinib
ra
inflammatory
indications
companies
conducting
global
studies
investigating
potential
role
jyseleca
variety
diseases
including
previously
reported
phase
selection
trial
ulcerative
colitis
information
clinical
trials
jyseleca
accessed
gilead
sciences
gilead
sciences
biopharmaceutical
company
discovers
develops
commercializes
innovative
medicines
areas
unmet
medical
need
company
strives
transform
simplify
care
people
illnesses
around
world
gilead
operations
countries
worldwide
headquarters
foster
city
california
information
gilead
sciences
please
visit
company
website
galapagos
galapagos
nv
discovers
develops
small
molecule
medicines
novel
modes
action
three
show
promising
patient
results
currently
development
multiple
diseases
pipeline
comprises
discovery
phase
programs
inflammation
fibrosis
osteoarthritis
indications
ambition
become
leading
global
biopharmaceutical
company
focused
discovery
development
commercialization
innovative
medicines
information
gilead
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
subject
risks
uncertainties
factors
also
possibility
unfavorable
results
ongoing
additional
clinical
trials
involving
ﬁlgotinib
possible
parties
may
make
strategic
decision
discontinue
development
ﬁlgotinib
result
ﬁlgotinib
may
never
successfully
commercialized
statements
statements
historical
fact
statements
could
deemed
statements
risks
uncertainties
factors
could
cause
actual
results
diﬀer
materially
referred
statements
reader
cautioned
rely
statements
risks
described
detail
gilead
form
quarter
ended
june
filed
securities
exchange
commission
statements
based
information
currently
available
gilead
gilead
assumes
obligation
update
statements
galapagos
statement
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
amended
subject
risks
uncertainties
factors
could
cause
actual
results
diﬀer
materially
referred
statements
therefore
reader
place
undue
reliance
risks
uncertainties
factors
include
without
limitation
inherent
risks
associated
clinical
trial
product
development
activities
competitive
developments
regulatory
approval
requirements
including
risk
data
ongoing
planned
clinical
research
programs
filgotinib
may
support
registration
development
due
safety
efficacy
reasons
timing
likelihood
additional
regulatory
authorities
approval
marketing
authorization
filgotinib
additional
regulatory
authorities
requiring
additional
studies
galapagos
reliance
collaborations
third
parties
including
collaboration
gilead
filgotinib
uncertainty
regarding
estimates
commercial
potential
filgotinib
well
risks
uncertainties
identified
annual
report
form
year
ended
december
subsequent
filings
sec
statements
statements
historical
fact
statements
could
deemed
statements
statements
contained
herein
based
management
current
expectations
beliefs
speak
date
hereof
galapagos
makes
commitment
update
publicly
release
revisions
statements
order
reflect
new
information
subsequent
events
circumstances
changes
expectations
full
european
summary
product
characteristics
jyseleca
available
ema
website
gilead
gilead
logo
trademarks
gilead
sciences
related
companies
contacts
galapagos
investors
media
elizabeth
goodwin
carmen
vroonen
vp
ir
global
head
communications
public
affairs
sofie
van
gijsel
anna
gibbins
senior
director
ir
senior
communications
director
therapeutic
areas
ir
communications
contacts
gilead
investors
media
douglas
maffei
phd
jennifer
wilson
product
characteristics
foster
city
usa
gilead
sciences
disease
control
prevention
rheumatoid
arthritis
ra
available
https
arthritis
basics
accessed
september
rheumatoid
arthritis
society
nras
european
fit
work
report
available
https
accessed
september
et
al
economic
evaluation
tofacitinib
treatment
rheumatoid
arthritis
methotrexate
tnf
inhibitors
us
payer
perspective
journal
managed
care
specialty
pharmacy
doi
et
al
eular
recommendations
management
rheumatoid
arthritis
synthetic
biological
antirheumatic
drugs
update
annals
rheumatic
disease
doi
c
et
al
integrated
safety
analysis
filgotinib
treatment
rheumatoid
arthritis
clinical
trials
abstract
european
congress
rheumatology
eular
et
al
filgotinib
provided
rapid
sustained
improvements
functional
status
pain
quality
life
fatigue
patients
rheumatoid
arthritis
inadequate
response
methotrexate
results
finch
study
abstract
european
congress
rheumatology
eular
et
al
efficacy
safety
filgotinib
patients
rheumatoid
arthritis
inadequate
response
methotrexate
finch
results
abstract
acr
arp
annual
meeting
et
al
efficacy
safety
filgotinib
patients
rheumatoid
arthritis
inadequate
response
methotrexate
finch
primary
outcome
results
annals
rheumatic
diseases
et
al
effect
filgotinib
vs
placebo
clinical
response
patients
moderate
severe
rheumatoid
arthritis
refractory
antirheumatic
drug
therapy
finch
randomized
clinical
trial
published
correction
appears
jama
feb
jama
et
al
efficacy
safety
filgotinib
patients
rheumatoid
arthritis
finch
results
annals
rheumatic
diseases
et
al
filgotinib
provided
rapid
sustained
improvements
functional
status
pain
health
related
quality
life
reduced
fatigue
time
patients
rheumatoid
arthritis
results
finch
study
abstract
european
congress
rheumatology
eular
et
al
efficacy
safety
filgotinib
patients
rheumatoid
arthritis
naïve
methotrexate
therapy
finch
primary
outcome
results
annals
rheumatic
diseases
based
placebo
controlled
pre
rescue
period
week
pooled
across
finch
darwin
patients
received
filgotinib
summary
product
characteristics
table
foster
city
usa
gilead
sciences
gilead
galapagos
filgotinib
clinical
program
trial
details
finch
finch
finch
selection
diversity
penguin
penguin
attachment
